{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029646","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.349033+00:00","generated_at":"2026-06-13T18:39:18.231640+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Heron Therapeutics appoints Ira Duarte as CFO effective June 16, 2023","bullets":["Ira Duarte named CFO; previously CFO of Veloxis Pharmaceuticals and held finance roles at BioDelivery Sciences, Chiesi USA, and Ernst & Young.","Compensation includes $500K base salary, $250K target bonus (pro-rated for 2023), and inducement award of options for 800K shares, 50K RSUs, and performance options for up to 500K shares.","Inducement award granted outside 2007 Plan with four-year vesting for options and RSUs; performance options vest based on stock price goals.","Duarte also holds a board seat at TerrAscend Corp. since December 2022 and is a CPA with a BS in Accounting from Florida Atlantic University."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029646","json":"https://secwatch.observer/filing/0000950170-23-029646.json","markdown":"https://secwatch.observer/filing/0000950170-23-029646.md","text":"https://secwatch.observer/filing/0000950170-23-029646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/0000950170-23-029646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/hrtx-20230616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T18:39:18.231640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb250c8b65","claim":"Ira Duarte was appointed as Chief Financial Officer at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"appointed Ira Duarte as Chief Financial Officer, effective June 16, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023029646/0000950170-23-029646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}